Novavax (NVAX) Current Deferred Revenue (2011 - 2026)
Novavax's Current Deferred Revenue came in at $86.58 million for Q2 2026, down 23.9% from $113.76 million a year earlier and down 2.5% from the prior quarter.
Powered by 
Analysis
Novavax (NVAX) Current Deferred Revenue (2011 - 2026) Analysis & Trends
At the end of FY2025, Novavax's Current Deferred Revenue was $140.05 million, down 79.3% from FY2024.
- Current Deferred Revenue carries a five-year compound annual growth rate of -14.1% (FY2020 to FY2025).
- Going back by year, Current Deferred Revenue was $675.07 million in FY2024 (+179.8%), $241.31 million in FY2023 (-39.7%), $400 million in FY2022 (-71.4%) and $1.4 billion in FY2021 (+366.7%).
- The Q2 2026 figure represents the lowest quarterly Current Deferred Revenue since Q3 2020.
- Year-over-year, Current Deferred Revenue has declined for six consecutive quarters, with growth averaging 7.1% over the last eight quarters.
- The fastest year-over-year change in Current Deferred Revenue over five years came in Q4 2021 (growth of 366.7%), and the weakest in Q3 2025 (a decline of 83.0%).
- Business Quant data shows NVAX's Current Deferred Revenue at $88.77 million (Q1 2026), $140.05 million (Q4 2025) and $104.25 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Novavax | 1.78 Bn | -1.23 Bn | 42.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 86.58 Mn |
| Mar 31, 2026 | 88.77 Mn |
| Dec 31, 2025 | 140.05 Mn |
| Sep 30, 2025 | 104.25 Mn |
| Jun 30, 2025 | 113.76 Mn |
| Mar 31, 2025 | 108.33 Mn |
| Dec 31, 2024 | 675.07 Mn |
| Sep 30, 2024 | 613.42 Mn |
| Jun 30, 2024 | 666.39 Mn |
| Mar 31, 2024 | 240.90 Mn |
| Dec 31, 2023 | 241.31 Mn |
| Sep 30, 2023 | 192.19 Mn |
| Jun 30, 2023 | 300.47 Mn |
| Mar 31, 2023 | 415.76 Mn |
| Dec 31, 2022 | 400.00 Mn |
| Sep 30, 2022 | 404.80 Mn |
| Jun 30, 2022 | 701.52 Mn |
| Mar 31, 2022 | 1.10 Bn |
| Dec 31, 2021 | 1.40 Bn |
| Sep 30, 2021 | 1.30 Bn |
API Access
Novavax Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NVAX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "NVAX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NVAX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();